109 related articles for article (PubMed ID: 19726540)
1. Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.
Dahan L; Bonnetain F; Rougier P; Raoul JL; Gamelin E; Etienne PL; Cadiot G; Mitry E; Smith D; Cvitkovic F; Coudert B; Ricard F; Bedenne L; Seitz JF; ;
Endocr Relat Cancer; 2009 Dec; 16(4):1351-61. PubMed ID: 19726540
[TBL] [Abstract][Full Text] [Related]
2. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
Sun W; Lipsitz S; Catalano P; Mailliard JA; Haller DG;
J Clin Oncol; 2005 Aug; 23(22):4897-904. PubMed ID: 16051944
[TBL] [Abstract][Full Text] [Related]
3. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.
Engstrom PF; Lavin PT; Moertel CG; Folsch E; Douglass HO
J Clin Oncol; 1984 Nov; 2(11):1255-9. PubMed ID: 6238136
[TBL] [Abstract][Full Text] [Related]
4. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
Yao JC; Phan A; Hoff PM; Chen HX; Charnsangavej C; Yeung SC; Hess K; Ng C; Abbruzzese JL; Ajani JA
J Clin Oncol; 2008 Mar; 26(8):1316-23. PubMed ID: 18323556
[TBL] [Abstract][Full Text] [Related]
5. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial.
Janson ET; Rönnblom L; Ahlström H; Grandér D; Alm G; Einhorn S; Oberg K
Ann Oncol; 1992 Sep; 3(8):635-8. PubMed ID: 1450046
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours.
Hughes MJ; Kerr DJ; Cassidy J; Soukop M; McGregor K; Blackburn N; Yosef H; Kaye SB
Ann Oncol; 1996 Feb; 7(2):208-10. PubMed ID: 8777180
[TBL] [Abstract][Full Text] [Related]
7. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.
Yao JC; Guthrie KA; Moran C; Strosberg JR; Kulke MH; Chan JA; LoConte N; McWilliams RR; Wolin EM; Mattar B; McDonough S; Chen H; Blanke CD; Hochster HS
J Clin Oncol; 2017 May; 35(15):1695-1703. PubMed ID: 28384065
[TBL] [Abstract][Full Text] [Related]
8. Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.
Zilembo N; Buzzoni R; Bajetta E; Di Bartolomeo M; de Braud F; Castellani R; Maffioli L; Celio L; Villa E; Lorusso V
Acta Oncol; 1993; 32(2):245-50. PubMed ID: 8391833
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Kirchner H; Jonas U; Bergmann L; Schott H; Heynemann H; Fornara P; Loening SA; Roigas J; Müller SC; Bodenstein H; Pomer S; Metzner B; Rebmann U; Oberneder R; Siebels M; Wandert T; Puchberger T; Reitz M;
J Clin Oncol; 2004 Apr; 22(7):1188-94. PubMed ID: 14981107
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
[TBL] [Abstract][Full Text] [Related]
12. Experience in treatment of metastatic pulmonary carcinoid tumors.
Granberg D; Eriksson B; Wilander E; Grimfjärd P; Fjällskog ML; Oberg K; Skogseid B
Ann Oncol; 2001 Oct; 12(10):1383-91. PubMed ID: 11762808
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.
Moertel CG; Hanley JA
Cancer Clin Trials; 1979; 2(4):327-34. PubMed ID: 93982
[TBL] [Abstract][Full Text] [Related]
14. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
[TBL] [Abstract][Full Text] [Related]
16. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study.
Bukowski RM; Johnson KG; Peterson RF; Stephens RL; Rivkin SE; Neilan B; Costanzi JH
Cancer; 1987 Dec; 60(12):2891-5. PubMed ID: 2960446
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
